Trial Profile
Exploring the microbiome in patients with advanced biliary tract cancer in a first-line study of durvalumab (MEDI4736) in combination with cisplatin/gemcitabine
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 24 Nov 2023
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Durvalumab (Primary) ; Gemcitabine (Primary)
- Indications Adenocarcinoma; Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
- Acronyms ABC-12
- 02 Nov 2023 Status changed from not yet recruiting to recruiting.
- 06 Jun 2023 Trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 19 May 2023 Planned initiation date changed from 28 Feb 2023 to 31 Aug 2023.